10 Best Medical Stocks Under $20

Published on December 12, 2022 at 9:53 am by Hamna Asim in Hedge Funds, News

In this article, we discuss 10 best medical stocks under $20. If you want to see more stocks in this selection, check out 5 Best Medical Stocks Under $20.

The healthcare industry has undergone a significant restructuring in the wake of the COVID-19 pandemic. There were multiple new healthcare trends in 2022 that have a lasting impact on the industry. These include telemedicine, electronic health records, medical internet of things (IoT), remote monitoring using real-time health data and metrics, artificial intelligence, and improved workflows in the industry.

Concerned investors are turning over every leaf in the capital markets while they look for stocks that have a combination of high growth potential and a history of surviving during economic downturns. Health care is often considered an “Energizer bunny” sector, with sustainable revenues from continuously resilient demand. This is because the US has strong healthcare demand from aging baby boomers, and more than 10,000 of them turn 65 years old every day. In the United States, approximately 20% of the gross domestic product is generated from the healthcare industry.

According to McKinsey & Co, the healthcare sector’s EBITDA rose 5% annually between 2017 and 2019, and was flat during 2020 to 2021. McKinsey expects the sector EBITDA, a primary measure of earnings strength, to grow 6% annually from 2021 through 2025, generating an extra $31 billion in profits.

Some of the best medical stocks to invest in include AbbVie Inc. (NYSE:ABBV), UnitedHealth Group Incorporated (NYSE:UNH), and Abbott Laboratories (NYSE:ABT). However, we discuss medical stocks under $20 in this article.

Our Methodology

We selected medical stocks priced under $20 so that beginner investors with limited money can venture into the healthcare sector as well. The following stocks were chosen based on positive analyst coverage, strong business fundamentals, and future growth potential. We have assessed the hedge fund sentiment from Insider Monkey’s database of 920 elite hedge funds tracked as of the end of the third quarter of 2022.

national-cancer-institute-GcrSgHDrniY-unsplash

Best Medical Stocks Under $20

10. Abcam plc (NASDAQ:ABCM)

Number of Hedge Fund Holders: 9

Share Price as of December 8: $15.67

Abcam plc (NASDAQ:ABCM) incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. It is a life science company that specializes in identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery end-markets.

On November 9, NanoString Technologies, Inc. (NASDAQ:NSTG) and Abcam plc (NASDAQ:ABCM) announced the expansion of their collaboration to advance spatial multi-omics research. Under this agreement, both companies will co-market Abcam antibodies for NanoString’s high-plex spatial multi-omic solutions.

Investment advisory RBC Capital on September 14 raised the firm’s price target on Abcam plc (NASDAQ:ABCM) to 2,200 GBp from 1,700 GBp and maintained an Outperform rating on the shares. Analyst Charles Weston issued the ratings update.

According to Insider Monkey’s third quarter database, Abcam plc (NASDAQ:ABCM) was part of 9 hedge fund portfolios at the end of Q3 2022, with collective stakes worth $56.8 million, compared to 7 funds in the prior quarter worth $40 million. Rock Springs Capital Management held the leading position in the company, consisting of 2 million shares worth $30.5 million.

In addition to AbbVie Inc. (NYSE:ABBV), UnitedHealth Group Incorporated (NYSE:UNH), and Abbott Laboratories (NYSE:ABT), Abcam plc (NASDAQ:ABCM) is one of the best medical stocks to consider.

9. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Number of Hedge Fund Holders: 20

Share Price as of December 8: $13.10

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is a California-based life sciences company that offers drug therapies, diagnostics, novel vaccines, and research on human diseases in the United States and internationally. It is one of the best medical stocks to invest in.

On December 6, RBC Capital analyst Conor McNamara initiated coverage of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) with an Outperform rating and a $22 price target. The analyst views Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) as a “clear winner exiting the pandemic.” Demand for its CleanCap product, a vital component utilized in the Pfizer COVID vaccine, rose at the beginning of the pandemic with “long-lasting” financial and strategic benefits, the analyst told investors. He believes Maravai’s present valuation does not match the company’s growth opportunity in the near, medium, or long-term.

According to Insider Monkey’s data, 20 hedge funds were bullish on Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) at the end of September 2022, compared to 19 funds in the earlier quarter. Select Equity Group is the largest stakeholder of the company, with 16.45 million shares worth $420 million.

Here is what ClearBridge Mid Cap Strategy has to say about Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) in its Q3 2021 investor letter:

“The Strategy’s health care holdings were also a positive contributor during the quarter. The need for vaccines and vaccine-manufacturing inputs were a catalyst for the biotechnology and research & development industries. For instance, Maravai LifeSciences produces the chemicals needed in the development and stabilization of Messenger RNA (mRNA) for a growing market of disease research and treatments – expected to produce recurring revenue at high margins. In addition to being financially beneficial, the company’s role in helping manufacture the COVID-19 vaccine has accelerated developments within non-COVID mRNA vaccines and therapeutics expected to come to market over the next decade.”

8. Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Number of Hedge Fund Holders: 21

Share Price as of December 8: $9.58

Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a California-based company that designs, develops, and manufactures sequencing systems to resolve genetically complex problems. On November 16, Canaccord analyst Kyle Mikson raised the price target on Pacific Biosciences of California, Inc. (NASDAQ:PACB) to $14 from $12 and reiterated a Buy rating on the shares. The analyst attended the company’s investor day where he appreciated its long-term strategy, including the growing addressable market and penetration, its expanding product portfolio, and achievable financial targets.

According to Insider Monkey’s third quarter database, 21 hedge funds were long Pacific Biosciences of California, Inc. (NASDAQ:PACB), with collective stakes worth $277 million, compared to 18 funds in the prior quarter worth $226.5 million. Cathie Wood’s ARK Investment Management is the largest position holder in the company, with 28.7 million shares worth $166.5 million.

Here is what DEVON Equity Management has to say about Pacific Biosciences of California, Inc. (NASDAQ:PACB) in its Q2 2021 investor letter:

“As a final word on Sequencing – we established a position in Pacific Biosciences (PACB US) during the quarter. PacBio is the leader in Long Read Sequencing (Illumina is dominant in Short Read). The Long Read market is far less developed than short read, but our continued research into the genomic sequencing field increased our confidence in the commercial viability for Long Read Sequencing in the coming years. We will discuss the investment case for PacBio in more detail in a future letter.”

7. Haleon plc (NYSE:HLN)

Number of Hedge Fund Holders: 21

Share Price as of December 8: $7.80

Haleon plc (NYSE:HLN) was incorporated in 2021 and is headquartered in Brentford, the United Kingdom. The company engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, Parodontax, and Centrum. Haleon plc (NYSE:HLN) is one of the best medical stocks to consider.

On December 7, Barclays analyst Iain Simpson upgraded Haleon plc (NYSE:HLN) to Overweight from Equal Weight with a price target of 360 GBp, up from 298 GBp, after a U.S. federal judge rejected the scientific evidence behind more than 5,000 lawsuits claiming heartburn drug Zantac can cause cancer. Haleon plc (NYSE:HLN) is “investable again” now that the Zantac situation is “substantially derisked,” the analyst told investors in a research note.

According to Insider Monkey’s Q3 data, 21 hedge funds were bullish on Haleon plc (NYSE:HLN), with collective stakes worth $305.3 million.

6. Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Number of Hedge Fund Holders: 24

Share Price as of December 8: $1.80

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is a Massachusetts-based company that develops a platform for cell programming, which is used to program cells to allow biological production of novel therapeutics, food ingredients, and chemicals derived from petroleum. Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is one of the best medical stocks priced under $20. On December 8, Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) launched Ginkgo Enzyme Services, which helps in the development and discovery of novel enzyme activity through the optimization of enzyme function and large scale manufacturing.

On November 28, Berenberg analyst Gaurav Goparaju initiated coverage of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) with a Buy rating and a $6 price target. Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is leveraging its platform to industrialize synthetic biology at scale across diverse end-markets and has “the only scaled horizontal platform in the space,” said the analyst. He believes the company is “well-positioned to disrupt cell programming across industries.”

According to Insider Monkey’s data, 24 hedge funds were long Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) at the end of September 2022, compared to 29 funds in the prior quarter. The collective stakes held by elite funds in Q3 increased to $956 million from $575.7 million in Q2 2022.

Like AbbVie Inc. (NYSE:ABBV), UnitedHealth Group Incorporated (NYSE:UNH), and Abbott Laboratories (NYSE:ABT), Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is one of the best medical stocks favored by smart investors.

Click to continue reading and see 5 Best Medical Stocks Under $20.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on May 1, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up